Neoleukin Competitors

Delisted . USA . 
Stock . Neoleukin Therapeutics
NLTXDelisted Stock  USD 0.69  0.01  1.43%   
Neoleukin Therapeutics competes with CytomX Therapeutics, Spero Therapeutics, Instil Bio, NextCure, and Assembly Biosciences; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Neoleukin Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Neoleukin Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Neoleukin Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neoleukin Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.690.690.69
Details
Intrinsic
Valuation
LowRealHigh
0.630.630.76
Details
Naive
Forecast
LowNextHigh
0.560.560.56
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.600.780.96
Details

Neoleukin Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Neoleukin Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Neoleukin and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Neoleukin Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
NUVB
+ 0.62
SPRO
NUVB
+ 0.51
NXTC
NUVB
+ 0.5
CTMX
ACHL
+ 0.41
TIL
NXTC
+ 0.39
CTMX
ASMB
+ 0.35
TIL
  
High negative correlations   
NUVB
- 0.77
ACHL
ACHL
- 0.67
CTMX
ACHL
- 0.62
NXTC
NXTC
- 0.58
TIL
ASMB
- 0.42
NXTC
ACHL
- 0.39
SPRO

Risk-Adjusted Indicators

There is a big difference between Neoleukin Stock performing well and Neoleukin Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neoleukin Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Neoleukin Therapeutics Competitive Analysis

The better you understand Neoleukin Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Neoleukin Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Neoleukin Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NLTX CTMX SPRO TIL NXTC ASMB ACHL NUVB
 1.43 
 0.69 
Neoleukin
 4.59 
 1.04 
CytomX
 0.75 
 1.32 
Spero
 0.74 
 33.38 
Instil
 13.24 
 1.54 
NextCure
 0.98 
 16.57 
Assembly
 2.88 
 1.01 
Achilles
 2.66 
 2.93 
Nuvation
Market Volatility
(90 Days Market Risk)
Very steady
Dangerous
Unstable
Relatively risky
Risky
Relatively risky
Very risky
Very risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Modest
Good
Very Weak
Modest
OK
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
About Average
Very Small
Below Average
Above Average
Low
Below Average
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Strong Buy
Buy
Buy
Strong Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Hold
Strong Sell
Current Ratio
12.78 X
2.05 X
3.65 X
8.51 X
33.87 X
8.31 X
11.45 X
33.58 X
Net Asset
115.95 M
205.15 M
182.39 M
325.63 M
129.42 M
137.47 M
161.46 M
621.48 M
Profit Margin
N/A
0.11 %
0.15 %
N/A
N/A
(2.12) %
N/A
N/A
EBITDA
(56.48 M)
(4.31 M)
20.11 M
(85.78 M)
(63.95 M)
(64.2 M)
(70.44 M)
(99.6 M)
Current Valuation
(35.02 M)
(44.19 M)
12.76 M
155.74 M
(37.76 M)
3.57 M
(46.24 M)
475.12 M
Price To Book
0.44 X
5.04 X
0.89 X
1.12 X
0.50 X
2.99 X
0.37 X
2.02 X
Operating Margin
N/A
0.12 %
(1.87) %
N/A
N/A
(1.43) %
N/A
(66.16) %
Retained Earnings
(451.06 M)
(723.45 M)
(391.07 M)
(580.98 M)
(324.48 M)
(785.75 M)
(259.95 M)
(342.8 M)
Current Asset
289 K
189.75 M
7.3 M
N/A
46.99 M
68.37 M
N/A
N/A
Beta
1.1
1.06
0.63
1.74
0.79
0.59
1.34
1.36
Number Of Employees
7
120
46
49
82
65
204
203
Shares Outstanding
2.35 M
78.12 M
54.05 M
6.5 M
27.98 M
6.35 M
41.09 M
335.57 M
Cash Flow From Operations
(45.61 M)
(56.03 M)
(32.99 M)
(82.03 M)
(52.97 M)
22.74 M
(48.64 M)
(68 M)
Total Debt
12.07 M
13.97 M
5.54 M
86.05 M
6.61 M
2.34 M
4.62 M
4.01 M
Return On Equity
-0.38
-54.75
0.26
-0.49
-0.55
-1.02
-0.44
-0.96
Z Score
-5.73
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.19
0.0233
0.1
-0.12
-0.31
-0.35
-0.27
-0.14
Number Of Shares Shorted
26.4 K
5.67 M
387.07 K
376 K
66.12 K
7.95 K
159.25 K
9.97 M
Book Value Per Share
34.18 X
(0.30) X
1.49 X
29.98 X
4.10 X
7.50 X
2.81 X
1.50 X
Current Liabilities
1.02 M
15.74 M
6.04 M
N/A
5.53 M
3.4 M
N/A
N/A
Total Asset
115.95 M
205.15 M
182.39 M
325.63 M
129.42 M
137.47 M
161.46 M
621.48 M
Debt To Equity
0.11 %
0.67 %
0.19 %
0.12 %
0.01 %
0.04 %
0.04 %
0.01 %
Short Ratio
1.70 X
9.58 X
2.08 X
1.05 X
1.89 X
0.41 X
0.12 X
5.79 X
Target Price
1.5
5.29
5.0
103.67
3.33
35.5
2.83
6.5
Shares Owned By Institutions
45.58 %
72.58 %
26.13 %
75.20 %
57.50 %
18.79 %
62.47 %
44.10 %
Market Capitalization
8.2 M
81.39 M
71.34 M
218.73 M
38.09 M
105.32 M
44.41 M
1.01 B
Price To Earning
(4.60) X
(11.41) X
81.20 X
18.31 X
(25.44) X
(10.58) X
0.49 X
N/A
Price To Earnings To Growth
(0.03) X
(1.80) X
N/A
N/A
0.03 X
N/A
(0.31) X
N/A
Price To Sales
N/A
0.64 X
0.61 X
55,330 X
9.52 X
4.86 X
N/A
468.58 X
Net Income
(57.56 M)
(569 K)
22.81 M
(156.09 M)
(62.72 M)
(61.23 M)
(69.94 M)
(75.8 M)
Earnings Per Share
(12.28) X
0.15 X
0.34 X
(18.39) X
(2.19) X
(8.69) X
(1.59) X
(2.18) X
Shares Owned By Insiders
16.46 %
1.00 %
20.38 %
12.86 %
8.85 %
31.62 %
6.51 %
26.86 %
Revenue
N/A
101.21 M
96.73 M
N/A
N/A
7.16 M
N/A
N/A
Working Capital
88.07 M
27.02 M
94.06 M
150.2 M
105.84 M
94.56 M
128.64 M
602.46 M
Cash And Equivalents
116.46 M
194.29 M
45.4 M
354.61 M
185.49 M
116.69 M
201.6 M
703.8 M
Cash Per Share
2.73 X
2.94 X
1.29 X
2.73 X
6.68 X
2.41 X
4.94 X
3.22 X
Gross Profit
N/A
53.16 M
(42.11 M)
138 K
(54.2 M)
(63.9 M)
N/A
N/A
Day Typical Price
0.69
1.04
1.32
34.18
1.51
16.42
1.01
2.95
Accumulation Distribution
0.0563
40009.81
6564.1
13829.0
23726.25
798.42
1291.25
145245.0
Market Facilitation Index
0.04
N/A
N/A
0.0
0.0
0.0
N/A
N/A
Daily Balance Of Power
(0.25)
(1.00)
(0.20)
(0.08)
0.9
0.2286
(1.50)
(0.53)
Period Momentum Indicator
(0.01)
(0.05)
(0.01)
(0.25)
0.18
0.16
(0.03)
(0.08)
Rate Of Daily Change
0.99
0.95
0.99
0.99
1.13
1.01
0.97
0.97
Day Median Price
0.69
1.05
1.32
34.59
1.5
16.35
1.01
2.97
Price Action Indicator
(0.01)
(0.03)
N/A
(1.33)
0.13
0.3
(0.01)
(0.07)
Relative Strength Index
62.4
33.38
61.2
34.45
49.99
52.12
54.66
41.36
Coefficient Of Variation
(2,179)
(2,173)
3863.33
581.95
(138,272)
979.02
907.71
2820.61
Mean Deviation
2.25
2.48
1.86
9.15
2.41
3.06
1.99
3.61
Jensen Alpha
0.0304
(0.32)
0.004
2.0
(0.01)
0.3433
0.2793
(0.37)
Total Risk Alpha
(0.94)
(0.84)
(0.50)
(0.56)
(0.71)
(0.48)
(0.45)
(0.83)
Sortino Ratio
N/A
N/A
(0.04)
0.3427
N/A
0.062
0.1325
1.0E-4
Downside Variance
N/A
N/A
5.02
55.03
N/A
22.2
6.21
19.62
Standard Deviation
3.7
3.29
2.73
15.78
3.38
4.51
4.53
4.77
Kurtosis
13.95
1.93
3.29
12.11
3.08
3.28
38.83
0.3111
Potential Upside
4.05
5.0
5.56
20.63
5.22
8.79
3.03
9.48
Treynor Ratio
0.1359
(0.16)
0.1702
0.6158
3.89
0.6648
0.3705
0.0478
Maximum Drawdown
27.84
17.21
14.25
105.83
14.18
30.39
38.16
18.83
Variance
13.69
10.82
7.44
248.87
11.46
20.38
20.53
22.78
Market Risk Adjusted Performance
0.1459
(0.15)
0.1802
0.6258
3.9
0.6748
0.3805
0.0578
Risk Adjusted Performance
(0.03)
(0.03)
0.0271
0.1417
0.0072
0.0869
0.0931
0.0357
Skewness
(2.77)
0.845
1.42
3.06
0.9128
(0.17)
5.61
0.3182
Semi Deviation
N/A
N/A
1.83
6.27
N/A
4.26
1.61
4.22
Information Ratio
(0.09)
(0.1)
(0.04)
0.1611
(0.05)
0.0647
0.0729
1.0E-4
Value At Risk
(3.53)
(5.17)
(3.94)
(10.89)
(5.00)
(6.04)
(2.88)
(7.45)
Expected Short fall
N/A
N/A
(3.00)
(12.33)
N/A
(3.10)
(3.13)
(4.14)
Downside Deviation
N/A
N/A
2.24
7.42
N/A
4.71
2.49
4.43
Semi Variance
N/A
N/A
3.35
39.31
N/A
18.15
2.6
17.77

Neoleukin Therapeutics Competition Performance Charts

Five steps to successful analysis of Neoleukin Therapeutics Competition

Neoleukin Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Neoleukin Therapeutics in relation to its competition. Neoleukin Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Neoleukin Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Neoleukin Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Neoleukin Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Neoleukin Therapeutics position

In addition to having Neoleukin Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Moderate Funds Thematic Idea Now

Moderate Funds
Moderate Funds Theme
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Neoleukin Stock

If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
CEOs Directory
Screen CEOs from public companies around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY